ADC Therapeutics SA expected to post a loss of 67 cents a share - Earnings Preview

ADC Therapeutics SA

05/05/2023 14:02

* ADC Therapeutics SA  ADCT.N   ADCT.K  is expected to show
a fall
in quarterly revenue when it reports  results on May 9. 
    * The Epalinges Vaud-based  company is expected to report  a
56.8% decrease in revenue to $20.088 million from $46.5 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ADC Therapeutics SA
is
for a loss of 67 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 6.5%
in the last three months. ​
    * Wall Street's median 12-month price target for ADC
Therapeutics
SA is $12​, above​ its last closing price of $1.94. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.21       -0.29      -0.30     Missed  -4.6
 Sep. 30 2022  -0.30       -0.35      -0.65     Missed  -84.2
 Jun. 30 2022  -0.92       -0.91      -0.84     Beat    8.1​
 Mar. 31 2022  -0.69       -0.70      -0.22     Beat    68.4
 ​​Dec.        -0.86       -0.86      -0.45     Beat    47.5
 31 2021                                                
 Sep. 30 2021  -0.96       -0.92      -0.93     Missed  -1.4​
 Jun. 30 2021  -0.87       -0.86      -0.96     Missed  -11.6
 Mar. 31 2021  -0.92       -0.90      -0.46     Beat    49.2
 This summary was machine generated May 5 at 13:02 GMT.  All
figures in US dollars  unless otherwise stated